Asthma Lung Inflammation Allergies Air Pollution Allergic Rhinitis Air Filtration Short-term Health Risks Emphysema Sensitive Groups Air Quality Health Advisory
Humanization of the XA19 antibody is underway with clinical trials targeted to begin in two to three years.